Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.
Clinical trial NCT00099437 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT00099437
- Sponsor
- AstraZeneca
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2005-02-13
- Primary completion
- 2009-02-27
- Enrollment
- 736
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.